International Journal of Cardiology
Volume 141, Issue 1 , Pages 39-43 , 14 May 2010

The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure

  • Amalia Vaz Pérez

      Affiliations

    • Competence Network Heart Failure, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Wolfram Doehner

      Affiliations

    • Applied Cachexia Research, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Stephan von Haehling

      Affiliations

    • Applied Cachexia Research, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Hendrik Schmidt

      Affiliations

    • Department of Cardiology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
    • ,
  • Arabel V. Zimmermann

      Affiliations

    • Competence Network Heart Failure, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Hans-Dieter Volk

      Affiliations

    • Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Stefan D. Anker

      Affiliations

    • Applied Cachexia Research, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Mathias Rauchhaus

      Affiliations

    • Competence Network Heart Failure, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
    • Corresponding Author InformationCorresponding author. Competence Network Heart Failure, Department of Cardiology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Tel.: +49 30 450 576 815(Office), fax: +49 30 450 576 962.

Received 13 November 2008 ,Revised 20 November 2008 ,Accepted 22 November 2008.

References 

  1. Birkenfeld AL, Budziarek P, Boschmann M, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in man. Diabetes. 2008;
  2. Burnett JC, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231(4742):1145–1147
  3. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362–1374
  4. Raine AE, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986;315:533–537
  5. Nakaoka H, Imataka K, Amano M, Fujii J, Ishibashi M, Yamaji T. Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med. 1985;313:892–893
  6. Leinonen H, Naveri H, Tikkanen I, Sovijarvi A, Fyhrquist F. Basal and exercise plasma levels of atrial natriuretic factor in congestive heart failure. Am Heart J. 1988;116:209–211
  7. Schiffrin EL, Taillefer R. Correlation of left ventricular ejection fraction and plasma atrial natriuretic peptide in congestive heart failure. N Engl J Med. 1986;315:765–766
  8. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534–1539
  9. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N- terminal proatrial natriuretic peptide. Circulation. 1996;93:1963–1969
  10. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1353
  11. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824–839
  12. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534
  13. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077–1083
  14. Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997;18:259–269
  15. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534
  16. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206
  17. van Veldhuisen DJ, Boomsma F, de Kam PJ, et al. Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure. Eur Heart J. 1998;19:753–760
  18. Davis KM, Fish LC, Elahi D, Clark BA, Minaker KL. Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. JAMA. 1992;267:2625–2629
  19. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053
  20. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–241
  21. Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 2006;290:L622–L645
  22. Siednienko J, Jankowska EA, Banasiak W, Gorczyca WA, Ponikowski P. Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. Int J Cardiol. 2007;122:111–116
  23. Sharma R, Bolger AP, Rauchhaus M, et al. Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail. 2005;7:865–868
  24. Ladetzki-Baehs K, Keller M, Kiemer AK, et al. Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology. 2007;148:332–336
  25. Kiemer AK, Vollmar AM. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem. 1998;273:13444–13451
  26. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab. 2005;90:3622–3628
  27. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–3067
  28. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(08)01304-1

doi: 10.1016/j.ijcard.2008.11.146

International Journal of Cardiology
Volume 141, Issue 1 , Pages 39-43 , 14 May 2010

Article Tools

* Image Usage & Resolution